EMA issues advice on casirivimab and imdevimab antibody cocktail for the treatment of mild-to-moderate COVID-19

NEXT STORY
Skylight Health Appoints Andrew Elinesky as Chief Financial Officer
PREV STORY
Ascendis Pharma A/S Announces New “Outgrow GHD” Educational Resource to Support Rare Disease Day 2021
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Horizon Pharma plc Completes Sale of European Marketing Rights for PROCYSBI® (cysteamine bitartrate) delayed-release capsules and QUINSAIR™ (levofloxacin nebuliser solution) in Europe, Middle East and Africa (EMEA) Regions to Chiesi Farmaceutici S.p.A.

DUBLIN, Ireland, June 23, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) (Horizon), a ...

author_avatar
NASDAQ Market News

Novan Provides Corporate Update and Reports Third Quarter 2021 Financial Results

author_avatar
NASDAQ Market News

Vaxil Provides Update on Preclinical Experiment

author_avatar
NASDAQ Market News